



ISSN 3105-3629

Targeted Cancer Therapy Connect

A Journal Specialized in
Targeted Cancer Therapy and Immunotherapy

Editor-in-Chief
Eyad Elkord, PhD



SCIFINITI
PUBLISHING

Connecting Minds



OPEN ACCESS PEER-REVIEWED JOURNAL

www.scifiniti.com

Targeted Cancer Therapy Connect

A Journal Specialized in Targeted Cancer Therapy and Immunotherapy

Volume: 1, 2025

Subject Categories

Targeted Cancer Therapy

Immunotherapy

Precision Oncology

Target Audience

Targeted Cancer Therapy Connect provides a platform for researchers, clinicians, and practitioners to share their findings, discuss challenges, and explore new frontiers in the fight against cancer through immunological approaches.



Eyad Elkord

Editor-in-Chief

Department of Biological Sciences, School of Science
Xi'an Jiaotong-Liverpool University
Suzhou, China

Message from EiC

Targeted Cancer Therapy Connect is a peer-reviewed journal that aims to provide a platform for researchers and clinicians to share their latest findings and advancements in understanding the interactions between the immune system and cancer. Our goal is to foster collaboration and exchange of knowledge in this rapidly evolving area of research.

Aims and Scope

Targeted Cancer Therapy Connect is a peer-reviewed, open-access journal dedicated to understanding of the complex interactions between cancer cells and the immune system. The journal aims to publish innovative research and promote the dissemination of significant discoveries in cancer immunology.

Key Topics

Molecular Targets and Mechanisms – Discovery and validation of therapeutic targets; roles of oncogenes, tumor suppressors, signaling pathways, and the tumor microenvironment.

Targeted Therapeutics – Development of small-molecule inhibitors, monoclonal antibodies, antibody–drug conjugates (ADCs), peptide- and protein-based drugs, and next-generation modalities such as PROTACs.

Immunotherapy and Precision Oncology – Immune checkpoint inhibitors, bispecific antibodies, CAR-T and TCR-based therapies, vaccines, and biomarker-guided treatment strategies.

Drug Resistance and Combination Therapy – Mechanisms of resistance and rational combination regimens integrating targeted and immune-based agents.

Clinical Translation – Clinical trials of targeted agents, pharmacogenomics, predictive biomarkers, and case reports highlighting successful targeted interventions.

Technological and Methodological Advances – CRISPR, single-cell omics, proteomics, nanomedicine, and computational or AI-driven approaches for target discovery and drug development.



scifiniti.com/journals/targeted-cancer-therapy-connect



 MBZ City, Abu Dhabi, UAE

 +971 2 619 3031

 cancer.immunology@scifiniti.com